Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs

Experimental Lung Research

Volumn 30, Issue 1, 2004, Pages 31-42

  Wang, Ling ^a   Zhu, Du Ming ^a   Su, Xiao ^a   Bai, Chun Xue ^a   Ware, Lorraine B ^b   Matthay, Michael A ^c  

^a FUDAN UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; Endothelin; Endothelin receptor; Oleic acid; Pulmonary hypertension

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; OLEIC ACID; TEZOSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; HEART OUTPUT; HEMODYNAMIC MONITORING; LUNG INJURY; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE;

EID: 1642462970     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140490252821     Document Type: Article

References (37)

1. Yanagisawa M, Kurihara H, Kumura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332: 411-415.
2. Inoue A, Yanagisawa M, Y Takuwa, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad USA. 1989;86:2863-2867.
3. Firth JD, Ratcliffe PJ: Organ distribution of the three rat endotheline messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992;90:1023-1031.
4. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
5. Marciniak SJ, Plumpton C, Barker PJ, Huskisson NS, Davenport AP: Location of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol. 1992;5:175-182.
6. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding and endothelin receptor. Nature. 1990;348:730-732.
7. Shetty SS, Okada T, Webb RL, DelGrande D, Lappe RW: Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993;191:459-464.
8. Sumer MJ, Ca TR, Mundin JW, White DG, Watts IS: Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992;107:858-860.
9. Hori S, Komatsu Y, Shigemoto R, Mizuno N, Nakanishi S: Distinct tissue distribution and cellar location of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 1992;130:1885-1895.
10. Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, Sugishita Y, Goto K, Nishikibe M: Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol. 1994;76:1976-1982.
11. Maguire JJ, Davenport AP: ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191-197.
12. Allen SW, Chatfield BA, Koppenhafer SL, Schaffer MS, Wolfe RR, Abman SH: Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Associated with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis. 1993;148:519-522.
13. Stewart DJ, Levy RD, Cernack P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension:marker or mediator of disease? Ann Intern Med 1991;114:464-469.
14. Stelzner TJ, O'Brien F, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, McMurtry IF, Fisher JH: Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 1992;262:L614-L620.
15. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxia pulmonary hypertension in rats. J Appl Physiol. 1995;79: 2122-2131.
16. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S: Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxia rats. Am J Physiol Heart Circ Physiol. 1995;268:H828-H835.
17. Clozel M, Ramuz H, Clozel J, Breu V, Hess P, Loffler BM, Coassolo P, Roux S: Pharmacology of Tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 1999;290:840-846.
18. Ashbaugh DG, Uzawa T: Respiratory and hemodynamic changes after injection of free fatty acids. J Surg Res. 1968;8:417-423.
19. Kelman GR: Digital computer subroutine for the conversion of oxygen tension into saturation. J Appl Physiol. 1966;21:1375-1376.
20. 2 dissociation computations. J Appl Physiol. 1979;46:599-602.
21. 2, pH, temperature and hemoglobin saturation in the dog. J Appl Physiol. 1966;21:195-201.
22. Leeman M, Lejeune P, Clozel J, Vachiery JL, Melot C, Naeije R: Nature of pulmonary hypertension in canine oleic acid pulmonary edema. J Appl Physiol 1990;69:293-298.
23. Tucker A, McMurtry IF, Reeves JT, Alexander AF, Will DH, Grover RF: Lung vascular smooth muscle as a determinant of pulmonary hypertension at high altitude. Am J Physiol. 1975;228:762-767.
24. Fishman AP: Hypoxia on the pulmonary circulation. How and where it acts. Circ Res. 1976;38: 221-223.
25. DeMey JG, Vanhoutte PM: Anoxia and endothelium-dependent reactivity of the canine femoral artery. J Physiol Lond. 1983;335:65-74.
26. Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S, Elton TS: Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol. 1994;77:1451-1459.
27. Elton TS, Oparil S, Taylor GR, Hicks PH, Yang RH, Jin H, Chen YF: Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. AmJ Physiol. 1992;263 (6 pt 2):R1260-R1264.
28. Li H, Elton TS, Chen SJ, Oparil S: Acute hypoxia stimulates endothelin-A receptor gene expression in the lung of rats. Am J Physiol. Lung Cell Mol Physiol. 1994;266:L553-L560.
29. Coe Y, Haleen SJ, Welch KM, Coceani F: The endothelin-A-receptor antagonist PD 180988 (CI-1034) selectively reverses the pulmonary vasoconstrictor response to hypoxia in the lamb. J Cardiovasc Pharmacol. 2000;36 (5 Suppl 1):S331-S333.
30. Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S: The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol. 1997;29:713-725.
31. Haleen S, Schroeder R, Walker D, Quenby BE, Welch K, Hallak H, Uprichard A, Reiser J: Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxia pulmonary hypertension. J Cardiovasc Pharmacol. 1998;31 (Suppl 1):1S331-1S335.
32. Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W: The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J. 2001;142:340-349.
33. Amione GT, Young JB, Durand JB, Bozkurt B, Mann DL, Kobrin I, Pratt CM: Hemodynamic effects of Tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001;103:973-980.
34. Onishi K, Ohno M, Little W, Cheng CP: Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1999;288:1214-1222.
35. Hay DWP, Hubbard WC, Undem BJ: Relative contributions of direct and indirect mechanisms mediating endothelin-induced contractions of guinea-pig trachea. Br J Pharmacol. 1993;110:955-962.
36. Henry PJ, Rigby PJ, Self GJ, Preuss JM, Goldie RG: Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle. Br J Pharmacol. 1990;100:786-792.
37. Hay DWP, Luttman MA, Hubbard WC, Undem BJ: Endothelin receptor subtypes in human and guinea-pig pulmonary arteries. Br J Pharmacol. 1993;110:1175-1183.